article thumbnail

Supply chain middlemen ‘pocket half of US branded medicine spending’

pharmaphorum

Over the same period, total gross expenditures on brand and generic medicines nearly doubled – from $268 billion to $517 billion, according to the report. Growth in spending on branded medicines was driven “primarily by increases in payers’ statutory and negotiated rebates and fees,” it says.